These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 39127274)

  • 1. Conjugation of TLR7 and TLR7/8 agonists onto weak protein antigen via versatile oxime ligation for enhanced vaccine efficacy.
    Zhang RY; Wen Y; He CB; Zhou SH; Wu YH; Wang EY; Feng RR; Ding D; Du JJ; Gao XF; Guo J
    Int J Biol Macromol; 2024 Oct; 278(Pt 1):134620. PubMed ID: 39127274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The synthesis and preliminary immunological evaluation of a dual-adjuvant SARS-CoV-2 RBD vaccine: Covalent integration of TLR7/8 and iNKT cell agonists.
    Xu Y; Yang J; Meng X; Meng S; Sun T; Ding N; Zong C
    Int J Biol Macromol; 2024 Jun; 270(Pt 1):132258. PubMed ID: 38735613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant-Protein Conjugate Vaccine with Built-In TLR7 Agonist on S1 Induces Potent Immunity against SARS-CoV-2 and Variants of Concern.
    Zhang RY; Zhou SH; He CB; Wang J; Wen Y; Feng RR; Yin XG; Yang GF; Guo J
    ACS Infect Dis; 2022 Jul; 8(7):1367-1375. PubMed ID: 35748575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strategic development of a self-adjuvanting SARS-CoV-2 RBD vaccine: From adjuvant screening to enhanced immunogenicity with a modified TLR7 agonist.
    Meng X; Xu Y; Yang J; Meng S; Ding N; Sun T; Zong C
    Int Immunopharmacol; 2024 May; 132():111909. PubMed ID: 38554446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 6-(4-Amino-2-butyl-imidazoquinolyl)-norleucine: Toll-like receptor 7 and 8 agonist amino acid for self-adjuvanting peptide vaccine.
    Fujita Y; Hirai K; Nishida K; Taguchi H
    Amino Acids; 2016 May; 48(5):1319-29. PubMed ID: 26874701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel sialoglycan linkage for constructing adjuvant-protein conjugate as potent vaccine for COVID-19.
    Wen Y; Zhang RY; Wang J; Zhou SH; Peng XQ; Ding D; Zhang ZM; Wei HW; Guo J
    J Control Release; 2023 Mar; 355():238-247. PubMed ID: 36716860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The adjuvant effect of TLR7 agonist conjugated to a meningococcal serogroup C glycoconjugate vaccine.
    Donadei A; Balocchi C; Mancini F; Proietti D; Gallorini S; O'Hagan DT; D'Oro U; Berti F; Baudner BC; Adamo R
    Eur J Pharm Biopharm; 2016 Oct; 107():110-9. PubMed ID: 27388628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of novel synthetic TLR7/8 agonists as vaccine adjuvants.
    Smith AJ; Li Y; Bazin HG; St-Jean JR; Larocque D; Evans JT; Baldridge JR
    Vaccine; 2016 Aug; 34(36):4304-12. PubMed ID: 27402566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of Toll-like receptor 7/8 agonists as vaccine adjuvants.
    Vasilakos JP; Tomai MA
    Expert Rev Vaccines; 2013 Jul; 12(7):809-19. PubMed ID: 23885825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TLR7/8 adjuvant overcomes newborn hyporesponsiveness to pneumococcal conjugate vaccine at birth.
    Dowling DJ; van Haren SD; Scheid A; Bergelson I; Kim D; Mancuso CJ; Foppen W; Ozonoff A; Fresh L; Theriot TB; Lackner AA; Fichorova RN; Smirnov D; Vasilakos JP; Beaurline JM; Tomai MA; Midkiff CC; Alvarez X; Blanchard JL; Gilbert MH; Aye PP; Levy O
    JCI Insight; 2017 Mar; 2(6):e91020. PubMed ID: 28352660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancement of the Immunostimulatory Activity of a TLR7 Ligand by Conjugation to Polysaccharides.
    Shinchi H; Crain B; Yao S; Chan M; Zhang SS; Ahmadiiveli A; Suda Y; Hayashi T; Cottam HB; Carson DA
    Bioconjug Chem; 2015 Aug; 26(8):1713-23. PubMed ID: 26193334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TLR9 agonist, but not TLR7/8, functions as an adjuvant to diminish FI-RSV vaccine-enhanced disease, while either agonist used as therapy during primary RSV infection increases disease severity.
    Johnson TR; Rao S; Seder RA; Chen M; Graham BS
    Vaccine; 2009 May; 27(23):3045-52. PubMed ID: 19428918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthetic Toll-Like Receptor 4 (TLR4) and TLR7 Ligands Work Additively via MyD88 To Induce Protective Antiviral Immunity in Mice.
    Goff PH; Hayashi T; He W; Yao S; Cottam HB; Tan GS; Crain B; Krammer F; Messer K; Pu M; Carson DA; Palese P; Corr M
    J Virol; 2017 Oct; 91(19):. PubMed ID: 28724768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel Lipidated Imidazoquinoline TLR7/8 Adjuvants Elicit Influenza-Specific Th1 Immune Responses and Protect Against Heterologous H3N2 Influenza Challenge in Mice.
    Miller SM; Cybulski V; Whitacre M; Bess LS; Livesay MT; Walsh L; Burkhart D; Bazin HG; Evans JT
    Front Immunol; 2020; 11():406. PubMed ID: 32210973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipid conjugation of TLR7 agonist Resiquimod ensures co-delivery with the liposomal Cationic Adjuvant Formulation 01 (CAF01) but does not enhance immunopotentiation compared to non-conjugated Resiquimod+CAF01.
    Wilkinson A; Lattmann E; Roces CB; Pedersen GK; Christensen D; Perrie Y
    J Control Release; 2018 Dec; 291():1-10. PubMed ID: 30291987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conjugation of a Small-Molecule TLR7 Agonist to Silica Nanoshells Enhances Adjuvant Activity.
    Huang CH; Mendez N; Echeagaray OH; Weeks J; Wang J; Vallez CN; Gude N; Trogler WC; Carson DA; Hayashi T; Kummel AC
    ACS Appl Mater Interfaces; 2019 Jul; 11(30):26637-26647. PubMed ID: 31276378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Self-Adjuvanting Lipoprotein Conjugate αGalCer-RBD Induces Potent Immunity against SARS-CoV-2 and its Variants of Concern.
    Wang J; Wen Y; Zhou SH; Zhang HW; Peng XQ; Zhang RY; Yin XG; Qiu H; Gong R; Yang GF; Guo J
    J Med Chem; 2022 Feb; 65(3):2558-2570. PubMed ID: 35073081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-encapsulation of synthetic lipidated TLR4 and TLR7/8 agonists in the liposomal bilayer results in a rapid, synergistic enhancement of vaccine-mediated humoral immunity.
    Short KK; Miller SM; Walsh L; Cybulski V; Bazin H; Evans JT; Burkhart D
    J Control Release; 2019 Dec; 315():186-196. PubMed ID: 31654684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthetic Toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained, and broadly protective responses.
    Goff PH; Hayashi T; Martínez-Gil L; Corr M; Crain B; Yao S; Cottam HB; Chan M; Ramos I; Eggink D; Heshmati M; Krammer F; Messer K; Pu M; Fernandez-Sesma A; Palese P; Carson DA
    J Virol; 2015 Mar; 89(6):3221-35. PubMed ID: 25568203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent Advances in the Discovery and Delivery of TLR7/8 Agonists as Vaccine Adjuvants.
    Dowling DJ
    Immunohorizons; 2018 Jul; 2(6):185-197. PubMed ID: 31022686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.